3 COLUMBUS CIRCLE, NEW YORK, NY
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Amended material disclosure
Board Appointment - Tim Ruan and Yi Zhang Join Indaptus Therapeutics Board
CFO Resignation; Nir Sassi Steps Down, Qinglai Lu Appointed Director
Changes in Control; David E. Lazar Acquires Preferred Stock
News, Articles of Incorporation
Warrant Repricing Agreement - Indaptus Therapeutics Reduces Exercise Prices
Salary Adjustments for Executive Officers - Indaptus Therapeutics, Inc.
Q1
FY 2025
Q3
Q2
FY 2024
Amended Registration Statement for Securities
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement